Hard work pays off! Kudos for the CLL new treatment option enlistment in Hong Kong

We're thrilled to announce that the next-generation BTKi has been successfully enlisted on the Hong Kong Hospital Authority's Drug Formulary.

Last June, Orbit Dot organized a press conference advocating for this significant inclusion, highlighting the need for enhanced treatment options for CLL patients. This will provide patients with more effective treatment choices and improve their quality of life.

Delighted to contribute to healthcare advocacy and support initiatives that prioritize patient access to new therapies! 

Read full release: https://lnkd.in/gqn7DHzX